Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to combat obesity. Is TERN stock a good buy right now?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
NASH treatments are projected to be one of the most sought-after indications in the coming years.
NASH is a surprisingly common ailment, and the first treatments are on the way.
Does Terns Pharmaceuticals, Inc. (TERN) have what it takes to be a top stock pick for momentum investors? Let's find out.
The company is showing progress toward a NASH therapy.
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Does Terns Pharmaceuticals, Inc. (TERN) have what it takes to be a top stock pick for momentum investors? Let's find out.
March S&P 500 futures (ESH23) are trending down -0.08% this morning after three major U.S. benchmark indices closed lower for a fourth straight session, with Nasdaq dropping the most as market participants'...
Terns Pharmaceuticals, AllianceBernstein Holding and ALLETE have been highlighted in this Screen of The Week article.